KDR and neoplasm: BZD can reverse the abnormal expression of PI3K, AKT, MYC, EGFR, HIF-1A, VEGFR, JUN, STAT3, CASP3, and TP53 genes in the tumor microenvironment and inhibit the progression of colorectal cancer by regulating the signaling pathways such as PI3K-AKT, P53, and VEGF.